This inventor holds 2 USPTO granted patents. Top assignee: Sloan-Kettering Institute for Cancer Research. Active years: 2006-2011.
Company Filing History:
Years Active: 2006-2011
Title: Innovations by Boris Zemelman
Introduction
Boris Zemelman is a prominent inventor based in New York, NY (US). He has made significant contributions to the field of biotechnology, particularly in the development of methods for activating genetically designated target cells. With a total of 2 patents, his work has implications for various applications in neuroscience and drug screening.
Latest Patents
Zemelman's latest patents include "Heterologous stimulus-gated ion channels and methods of using same" and "Bio-synthetic photostimulators and methods of use." The first patent focuses on methods and compositions that utilize heterologous stimulus-gated ion channels to activate target cells artificially, either in vivo or in vitro. This innovative approach allows for selective activation of cells using physical or chemical stimuli, which can be beneficial for neuronal mapping and drug screening. The second patent describes a method for rendering non-photoreceptor cells sensitive to light stimulation by introducing specific nucleic acid sequences. This process enables the conversion of rhodopsin to metarhodopsin, triggering intracellular responses that increase the concentration of important ions within the cell.
Career Highlights
Boris Zemelman is affiliated with the Sloan-Kettering Institute for Cancer Research, where he continues to advance his research in cell activation and stimulation. His work is characterized by a strong focus on innovative techniques that enhance our understanding of cellular mechanisms.
Collaborations
Zemelman collaborates with Gero Miesenböck, a fellow researcher known for his contributions to the field of optogenetics. Their partnership exemplifies the collaborative spirit in scientific research, leading to groundbreaking advancements in biotechnology.
Conclusion
Boris Zemelman is a notable inventor whose work in biotechnology has led to significant advancements in the activation of target cells. His patents reflect a commitment to innovation and collaboration in the scientific community.